ClinicalTrials.gg
Active, not recruitingNCT02068586Updated Oct 22, 2026

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

A Phase 2 interventional study of Sunitinib and Valproic Acid in Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size and Iris Melanoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Phase 2, Interventional, and Treatment

How we know

Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 191 studies in Uveal Melanoma with a site in United States — 26 open to participants now, 51 under way, 7 of them phase 3. Uveal Melanoma · United States.

Planned enrollment
13th of 163
210 · median 36
Started
2014
with 6 others
Phase 2
79 of 191
7 open now
Primary completion
2027-12
later than 30 of 50 live
Registered
90th of 191
by date

Among the 191 studies in Uveal Melanoma with a site in United States, this one is the 13th largest by planned enrollment of the 163 interventional ones that give a count, is one of 7 that started in 2014, is one of 79 in phase 2, reaches primary completion later than 30 of the 50 other live ones, and was the 90th registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

26 of the 191 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Uveal Melanoma with a site in United States, or all of them as a file.
02

Study summary

This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body. Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents these cells from growing. Valproic acid may change the expression of some genes in uveal melanoma and suppress tumor growth.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess the efficacy of adjuvant sunitinib malatate (sunitinib) and adjuvant valproic acid used for 6 months to improve overall survival (OS) at 2 years in patients with high risk uveal melanoma. (Cohort 1) II. To assess the efficacy of adjuvant sunitinib used for 12 months to improve 1.5-year relapse free survival (RFS) in patients with high-risk uveal melanoma. (Cohort 2) III. To assess whether the combination of sunitinib and valproic acid used for 12 months improve the 2-year relapse free survival (RFS) in patients with high-risk uveal melanoma. (Cohort 3)

SECONDARY OBJECTIVES:

I. To assess the efficacy of adjuvant sunitinib, in terms of RFS and adjuvant valproic acid used for 6 months in preventing the development of distal metastases in patients with high risk uveal melanoma. (Cohort 1) II. To assess the efficacy of adjuvant sunitinib, in terms of OS, used for 12 months in patients with high risk uveal melanoma. (Cohort 2) III. To assess the efficacy of adjuvant sunitinib in combination with valproic acid, in terms of OS in patients with high risk uveal melanoma. (Cohort 3) IV. To confirm the safety and tolerability of 6 months of adjuvant sunitinib and adjuvant valproic acid. (Cohort 1) V. To confirm the safety and tolerability of 12 months of adjuvant sunitinib. (Cohort 2) VI. To confirm the safety and tolerability of 12 months of adjuvant sunitinib and valproic acid. (Cohort 3)

TERTIARY OBJECTIVES:

I. To determine whether blood myeloid-derived suppressor cells (MDSCs) concentration and other inflammatory cytokines correlates with OS and RFS.

OUTLINE: Patients are assigned to 1 of 3 cohorts.

COHORT 1: Participants are randomized to 1 of 2 arms.

ARM I: Patients receive sunitinib malate orally (PO) daily for 6 months in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive valproic acid PO daily for 6 months in the absence of disease progression or unacceptable toxicity.

COHORT 2: Patients receive sunitinib malate PO daily for 12 months in the absence of disease progression or unacceptable toxicity.

COHORT 3: Patients receive sunitinib malate PO daily and valproic acid PO daily for 12 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

03

Conditions studied

  • Ciliary Body and Choroid Melanoma, Medium/Large Size
  • Ciliary Body and Choroid Melanoma, Small Size
  • Iris Melanoma
  • Stage I Intraocular Melanoma
  • Stage IIA Intraocular Melanoma
  • Stage IIB Intraocular Melanoma
  • Stage IIIA Intraocular Melanoma
  • Stage IIIB Intraocular Melanoma
  • Stage IIIC Intraocular Melanoma
  • Stage I Uveal Melanoma AJCC V7
  • Stage II Uveal Melanoma AJCC V7
  • Stage III Uveal Melanoma AJCC V7

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years old
  • -confirmed primary uveal melanoma
  • Definitive local treatment for primary tumor, including surgical resection (enucleation) or radiation therapy (radioactive plaque or external proton beam)
  • High risk for distal recurrence defined as any of the following conditions: A) Confirmed both monosomy 3 and 8q amplification; B) Class II tumor
  • Less than 6 months from the date that local treatment (surgical or radiation) of the primary tumor was finalized
  • performance status (PS) scores of 70 or greater
  • If female, no pregnancy
  • If of (\< one year ), must agree to practice an effective method of avoiding pregnancy (including oral or implanted , intrauterine device, condom, diaphragm with spermicidal, cervical cap, abstinence or sterile sex partner) from the time is signed (women only) or the time of initiation of sunitinib (sunitinib malate) (men only); both men and women must agree to continue using such precautions while receiving sunitinib or valproic acid and for 30 days after the final dose
  • (ANC) >= 1500/mm\^3
  • >= 100,000/mm\^3
  • >= 8 g/dl
  • Serum creatinine \< 1.5 times (ULN) or >= 40 ml/min
  • Serum \< 1.5 times ULN
  • Serum albumin > 2.0 g/dl
  • Adequate cardiac function ( [EF] > 50%) based on multi gated acquisition (MUGA) scan or 2 dimensional-echocardiogram (2D-Echo)
  • of at least 5 years

Exclusion criteria

Exclusion Criteria:

  • Other within 5 years, except curatively treated non-melanomatous skin cancer, curatively treated carcinoma in situ of the uterine cervix, or early stage (stage I or IIa) prostate cancer
  • uveal melanoma
  • History of severe allergic reaction to sunitinib or valproic acid; inability to receive sunitinib or valproic acid
  • Previous treatment with sunitinib or valproic acid for uveal melanoma
  • Active treatment with valproic acid for non-oncological conditions, if this cannot be safely switched to an alternative agent
  • Active epilepsy or convulsive conditions that require continuous use of anticonvulsants
  • Patients with known urea cycle disorders (i.e.: ornithine transcarbamylase deficiency)
  • Severe cardiovascular disease within 6 months, including myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebro-vascular accident or , pulmonary embolism, life threatening arrhythmias, uncontrollable hypertension or syndrome
  • Active liver disease (i.e., cirrhosis, viral or hepatitis, etc.)
  • Pregnancy or unwillingness to stop breast-feeding
  • Prior myelosuppressive chemotherapy or other drug therapy within the last 6 months prior to initiation of sunitinib or valproic acid
  • Current evidence of hematemesis, melena or gross hematuria
  • History or presence of any significant bleeding disorders
  • Concurrent use of a strong cytochrome P450 family 3, subfamily A, polypeptide 4 () inhibitor or inducer; these medications should be discontinued or switched to a different medication with a weaker CYP3A4 interaction prior to enrollment into the study; if patients need to continue the same medication(s), they are excluded from the study
  • Chronic usage of aspirin greater than 81 mg/day
  • Unable to render and to follow protocol requirements
  • Any other medical condition(s) that, at the discretion of the principal investigator (PI), would make the patient inappropriate for this study
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Sunitinib- (Cohort 1, Arm I)

    Patients receive sunitinib malate PO daily for 6 months in the absence of disease progression or unacceptable toxicity Quality-of-Life Assessment-Ancillary studies \- Laboratory Biomarker Analysis-Correlative studies

    Drug: Sunitinib

  • Experimental
    Valproic acid- (Cohort 1, Arm II)

    Patients receive valproic acid PO daily for 6 months in the absence of disease progression or unacceptable toxicity Quality-of-Life Assessment-Ancillary studies Laboratory Biomarker Analysis-Correlative studies

    Drug: Valproic Acid

  • Experimental
    Sunitinib Malate (Cohort 2)

    Patients receive sunitinib malate PO daily for 12 months in the absence of disease progression or unacceptable toxicity Quality-of-Life Assessment-Ancillary studies Laboratory Biomarker Analysis-Correlative studies

    Drug: Sunitinib Malate

  • Active comparator
    Sunitinib Malate + Valproic Acid (Cohort 3)

    Patients receive sunitinib malate PO daily and valproic acid PO daily for 12 months in the absence of disease progression or unacceptable toxicity. Quality-of-Life Assessment-Ancillary studies Laboratory Biomarker Analysis-Correlative studies

    Drug: Sunitinib Malate + Valproic Acid

Interventions

  • Given PO

    Also known as: Sunitinib malate, Sutent, SU11248, 341031-54-7 Butanedioic acid

  • Given PO

    Also known as: VPA, Valproate, Valproate sodium, Depakote, Epilim, Valparin, Valpro, Stavzor, Depakene, Di-n-propylacetic Acid

  • DrugSunitinibStudies of SunitinibSunitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: sunitinib, Sutent, SU011248

  • DrugSunitinib Malate + Valproic Acid

    Drug pages: SunitinibStudies of SunitinibSunitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Valproic AcidStudies of Valproic AcidValproic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: Sunitinib Malate, sunitinib, Sutent, SU011248, Valproic Acid, VPA, Valproate, Valproate sodium, Depakote, Epilim, Valparin, Valpro, Stavzor, Depakene, Di-n-propylacetic Acid

06

What researchers measure

Primary outcomes

  1. Overall survival (Cohort 1)

    OS distribution will be summarized using the method of Kaplan-Meier and the 2-year OS rate with two-sided 90% confidence interval (CI) will be provided. OS will be compared to the historic OS using a one-sample log-rank test.

    Time frame: Time of definitive treatment of the primary tumor until death from any cause, assessed at 2 years

  2. Relapse-free survival (RFS) (Cohort 2 and 3)

    RFS distribution will be summarized using the method of Kaplan-Meier. 1.5-year, 2-year PFS rate will be computed with the corresponding two-sided 90% confidence intervals. OS and RFS will be compared to the null hypothesis OS or RFS using a one-sided one-sample Brookmeyer-Crowley test with alpha 0.05

    Time frame: Time of definitive treatment of the primary tumor until confirmed metastatic relapse or death from any cause, assessed at 2 years

Secondary outcomes

  1. Relapse-free survival (Cohort 1)

    RFS distribution will be summarized using the method of Kaplan-Meier, and two-sided 90% confidence interval (CI) will be provided.

    Time frame: Time of definitive treatment of the primary tumor until confirmed metastatic relapse or death from any cause, assessed at 2 years

  2. Overall survival (Cohort 2)

    OS distribution will be summarized using the method of Kaplan-Meier and the 2-year OS rate with two-sided 90% confidence interval (CI) will be provided. OS will be compared to the historic OS using a one-sample log-rank test.

    Time frame: Time of definitive treatment of the primary tumor until death from any cause, assessed at 2 years

  3. Tolerability, defined as the proportion of patients able to complete 6 months of treatment, including those who underwent dose reduction

    Proportion of patients completing six months of treatment will be summarized using descriptive statistics.

    Time frame: 6 months

  4. Incidence of toxicity assessed according to the National Institute of Health Common Terminology Criteria for Adverse Events (NIH CTCAE) version 4.0

    Type and grade of toxicity will be assessed on every schedule visit and recorded based on NIH CTCAE 4.0 grading system. Descriptive statistics will be used to summarized type and grade of toxicity.

    Time frame: Up to 5 years

  5. Quality of life (QOL) assessed by Functional Assessment of Cancer Therapy-General (FACT-G) questionnaires

    The FACT-G questionnaires will be scored at baseline, 1 month, 3 months, and 6 months. The difference between two treatment groups will be analyzed with standard t-test at individual evaluation points. Average QOL scores during the study will be calculated and compared between the treatment groups. To estimate the magnitude of the difference between treatment groups, the standardized effect size and minimally important difference will be used. Repeated-measures mixed-effects models with random intercepts and slopes will be used to assess treatment differences in QOL measures over time.

    Time frame: Up to 6 months

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2014 (actual). Primary completion is estimated for Dec 2027, 157 months after the start.

Of 39 non-industry phase 2 interventional studies under Uveal Melanoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 95. This study's planned 157 months is above that.

Counting every sponsor, half of 46 studies reached it within 52 months; a quarter within 37 and three quarters within 84.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2014
First posted
Feb 21, 2014
StartActual
Nov 19, 2014
Primary completionEst.
Dec 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Dec 31, 2027
Oct 22, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Dec 31, 2026→Dec 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02068586
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Feb 21, 2014
Start date
Nov 19, 2014
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Takami Sato, MD
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sunitinib · Valproic Acid

Start the discussion